China Pharmaceutical announced that recently, Tianfang Pharmaceutical, its wholly-owned subsidiary, received the “Drug Supplement Application Approval Notice” for bumetanil injections approved and issued by the State Drug Administration. The marketing license holder for the drug was changed from Shenzhen Glenn Biomedical Technology Co., Ltd. to Tianfang Pharmaceutical. As of the date of disclosure of the announcement, the total investment in the project was about 1.465,200 yuan. In 2025, the sales volume of the drug in the six major markets of the three major terminals in China was about 262 million yuan, and in the first quarter of 2026, it was about 42.63 million yuan. This change has enriched the company's product line, but future drug sales may fall short of expectations.

China Pharmaceutical announced that recently, Tianfang Pharmaceutical, its wholly-owned subsidiary, received the “Drug Supplement Application Approval Notice” for bumetanil injections approved and issued by the State Drug Administration. The marketing license holder for the drug was changed from Shenzhen Glenn Biomedical Technology Co., Ltd. to Tianfang Pharmaceutical. As of the date of disclosure of the announcement, the total investment in the project was about 1.465,200 yuan. In 2025, the sales volume of the drug in the six major markets of the three major terminals in China was about 262 million yuan, and in the first quarter of 2026, it was about 42.63 million yuan. This change has enriched the company's product line, but future drug sales may fall short of expectations.